Exenatide may lessen CV risk in women with PCOS

  • Dawson AJ & al.
  • Front Endocrinol (Lausanne)
  • 1 Jan 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Exenatide (Byetta) is associated with weight loss and improvement in markers of cardiovascular (CV) risk (endothelial function, inflammation, and clot function) in overweight women with polycystic ovary syndrome (PCOS).

Why this matters

  • PCOS is linked to an adverse CV risk profile, whereas exenatide has been linked to improved insulin sensitivity and weight loss in patients with PCOS.

Key results

  • Exenatide was associated with weight loss (from 111.8 to 108.6 kg; P=.003) and reduced BMI (from 41.0 to 39.8 kg/m2; P=.005).
  • Exenatide was associated with reduced endothelial markers (intercellular adhesion molecule-1, going from 247.2 to 231.3 ng/mL [P=.02]; p-selectin, going from 101.1 to 87.4 ng/mL [P=.01]; e-selectin, going from 38.5 to 33.6 ng/mL [P=.03]).
  • Exenatide was associated with reduced inflammation (CRP, going from 8.5 to 5.6 mmol/L; P=.001) and a reduction in clot function (time from full clot formation to 50% lysis, going from 2987 to 1926 seconds; P=.02).

Study design

  • 30 overweight/obese women with PCOS who received exenatide, 20 who completed the study, were analyzed for weight changes and serum markers of CV risk.
  • Funding: Qatar National Library.

Limitations

  • Small patient sample size.
  • No control/placebo subjects.